TP53 modulates radiotherapy fraction size sensitivity in normal and malignant cells

Recent clinical trials in breast and prostate cancer have established that fewer, larger daily doses (fractions) of radiotherapy are safe and effective, but these do not represent personalised dosing on a patient-by-patient basis. Understanding cell and molecular mechanisms determining fraction size...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Scientific reports Jg. 11; H. 1; S. 7119 - 11
Hauptverfasser:	Anbalagan, Selvakumar, Ström, Cecilia, Downs, Jessica A., Jeggo, Penny A., McBay, David, Wilkins, Anna, Rothkamm, Kai, Harrington, Kevin J., Yarnold, John R., Somaiah, Navita
Format:	Journal Article
Sprache:	Englisch
Veröffentlicht:	London Nature Publishing Group UK 29.03.2021 Nature Publishing Group Nature Portfolio
Schlagworte:	631/337/1427 631/67/1059/485 Breast cancer Cell Line, Tumor Clinical trials Deoxyribonucleic acid DNA DNA - radiation effects DNA Breaks, Double-Stranded DNA End-Joining Repair DNA ligase (ATP) DNA-dependent protein kinase Dosage Fibroblasts Glioma Glioma cells Humanities and Social Sciences Humans Molecular modelling multidisciplinary Non-homologous end joining Prostate cancer Protein kinase C Radiation therapy Radiation Tolerance Radiotherapy Dosage Science Science (multidisciplinary) siRNA Tumor Suppressor Protein p53 - physiology Tumors
ISSN:	2045-2322, 2045-2322
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!